London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

Earlier this year, Intuitive Surgical warned that supplies may be tight in the months ahead as it continues to roll out the ...

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recogni | In ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...